Wolfe Research Initiates Coverage On LB Pharmaceuticals with Outperform Rating, Announces Price Target of $45
LB Pharmaceuticals, Inc.
LB Pharmaceuticals, Inc. LBRX | 0.00 |
Wolfe Research analyst Rudy Li initiates coverage on LB Pharmaceuticals (NASDAQ:
LBRX) with a Outperform rating and announces Price Target of $45.